If a biomarker is a picture of the current state of some biology, then a biosignal is a video of that state of biology.These biosignals – or ways of communicating – happen in multiple channels inside our bodies – streams like genomics, proteomics, metabolomics, and transcriptomics.
This is true multiomics.
The BPU can read all those types of mutiomics biosignals - in real-time.
Cardea’s proprietary BPU™ (Biosignal Processing Unit) Platform enables a game-changing new generation of more affordable, swift, precise, and comprehensive detection of multiple cancer biosignals. It is the first and only platform able to read all types of biosignals - true multiomics - allowing for detection of any cancer. For example, BPUs can do genomics via nucleic acid biosignals (e.g., ctDNA), proteomics via amino acid biosignals (e.g., immune-response), or even complex intercellular communication biosignals via exosomes – all from the same clinical sample on one platform.
Cardea's BPU offers an all-in-one platform for next gen liquid biopsy
The BPU’s ability to detect all types of cancer biosignals in combination with machine learning and AI will result in a breakthrough in protection against cancer via monitoring and timely response - not just sporadic testing. In addition, as BPUs are biocompatible semiconductors built with the nanomaterial graphene, they are small enough to become desktop instruments. Going from testing for single biomarkers via laboratory workflows to monitoring multiple cancer biosignals via one platform is the essence of this next generation of liquid biopsy, which can replace or enhance current liquid biopsy approaches.